Explore

Rapid Read Rapid Read
Challenges and Future Prospects of Brain Transplants Explored

Challenges and Future Prospects of Brain Transplants Explored

The concept of brain transplants remains a scientific challenge due to the complexity of forging connections between nerves in the central nervous system. Dr. Max Krucoff from the Medical College of Wisconsin explains that while peripheral nerves can regenerate, the central nervous system's ability to form new neurons is limited. Historical attempts at head transplants on animals have been largely unsuccessful, with ethical and scientific concerns surrounding human trials. Current research focuses on stem cell therapies and organoid grafts as potential methods to repair damaged brain tissue, though these are still in experimental stages.
Rapid Read Rapid Read
PCOS Renamed to Reflect True Nature of the Condition

PCOS Renamed to Reflect True Nature of the Condition

Polycystic ovary syndrome (PCOS) has been officially renamed to polyendocrine metabolic ovarian syndrome (PMOS) after a 14-year process involving over 14,000 patients and health professionals. The new name aims to more accurately describe the condition, which involves a large number of 'arrested follicles' rather than pathological ovarian cysts. This change is expected to improve diagnosis and treatment, as well as aid in identifying related conditions. The renaming is part of broader scientific updates, including research on pollution's impact on mental health and the discovery of Neanderthals as early dentists.
Trendline Trendline
Excimerlight Introduces Filter-Free 222nm Far-UVC Technology in North America

Excimerlight Introduces Filter-Free 222nm Far-UVC Technology in North America

Excimerlight Introduces Filter-Free 222nm Far-UVC Technology in North America
Rapid Read Rapid Read
New Stroke Trial Highlights Limitations of Artery Reopening in Patient Recovery

New Stroke Trial Highlights Limitations of Artery Reopening in Patient Recovery

A recent stroke trial conducted across 14 hospitals in Spain has revealed that reopening a blocked artery through thrombectomy is not always sufficient for patient recovery. The study, led by Dr. Arturo Renú, focused on the use of alteplase, a clot-dissolving drug, administered directly into the brain artery after thrombectomy. The trial involved 440 adults and aimed to address the issue of microcirculation blockages in small vessels that remain after the main artery is cleared. Results showed that patients receiving alteplase had a 57.5% rate of excellent functional outcomes compared to 42.5% in the thrombectomy-only group. However, the alteplase group also experienced a higher mortality rate of 12.1% compared to 6.4% in the thrombectomy-only group, indicating a need for further study on the safety of this approach.
Trendline Trendline
Excimerlight Expands into North America with New 222nm Far-UVC Technology for Disinfection

Excimerlight Expands into North America with New 222nm Far-UVC Technology for Disinfection

Excimerlight Expands into North America with New 222nm Far-UVC Technology for Disinfection
Trendline Trendline
Excimerlight Expands into North America with New 222nm Far-UVC Technology

Excimerlight Expands into North America with New 222nm Far-UVC Technology

Excimerlight Expands into North America with New 222nm Far-UVC Technology
Trendline Trendline
A*STAR Unveils Technique to Analyze RNA Structures for Disease Research

A*STAR Unveils Technique to Analyze RNA Structures for Disease Research

A*STAR Unveils Technique to Analyze RNA Structures for Disease Research
Trendline Trendline
Edesa Biotech Reports Increased Losses Amidst Strategic R Investments

Edesa Biotech Reports Increased Losses Amidst Strategic R Investments

Edesa Biotech Reports Increased Losses Amidst Strategic R Investments
Trendline Trendline
FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns

FDA Halts Aardvark Therapeutics' Prader-Willi Drug Trials Over Cardiac Concerns
Rapid Read Rapid Read
Study Reveals Hidden Cholesterol Risk in One in Five People, Suggests Need for Aggressive Management

Study Reveals Hidden Cholesterol Risk in One in Five People, Suggests Need for Aggressive Management

A new analysis involving over 20,000 patients from three major National Institutes of Health (NIH) studies has found that elevated levels of Lipoprotein(a) [Lp(a)] are linked to ongoing cardiovascular risk, even in individuals receiving standard treatment. The findings, presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2026 Scientific Sessions, indicate that patients with high Lp(a) levels may require more aggressive management of heart disease risk factors. Lp(a) is a cholesterol-carrying particle in the bloodstream that resembles LDL cholesterol but includes an extra protein, potentially making it more harmful. The study revealed that approximately 20% of people have elevated Lp(a) levels, which are often inherited and can increase heart disease risk even when standard cholesterol levels appear normal.
Rapid Read Rapid Read
HaysMed and Doctor Face $10 Million Lawsuit Following Patient's Death During Heart Surgery

HaysMed and Doctor Face $10 Million Lawsuit Following Patient's Death During Heart Surgery

HaysMed and Dr. Roberto Cervera are being sued for $10 million by Taasha Smith, the daughter of Stephen Richter, who died during an aortic valve replacement surgery in 2024. The lawsuit alleges negligence on the part of Dr. Cervera and HaysMed staff, citing multiple failures in evaluating and managing Richter's heart condition. The allegations include inadequate evaluation of Richter's condition, failure to provide necessary cardioplegia, and lack of informed consent regarding surgical risks and alternatives. The lawsuit was filed in Johnson County, and a request to change the venue to Ellis County was denied. HaysMed has expressed sympathy for the family but has not commented on the specific allegations due to ongoing litigation.
Trendline Trendline
Personalis to Engage with Investors at Upcoming Conferences

Personalis to Engage with Investors at Upcoming Conferences

Personalis to Engage with Investors at Upcoming Conferences